What Ppx Mceans: Everything You Need to Know

Last Updated on August 26, 2026 by Daniel Globe

PEP, or post-exposure prophylaxis, is a 28-day course of HIV medicines used after a possible exposure to reduce the chance of acquiring HIV. It is time-sensitive: treatment should start as soon as possible, ideally within 24 hours and no later than 72 hours after exposure. PEP may be considered after certain sexual, injection-related, sexual-assault, or occupational exposures, and a healthcare professional should assess the specific risk.

What Is PEP?

PEP stands for post-exposure prophylaxis. It uses antiretroviral medicines after a possible HIV exposure to help prevent the virus from establishing an infection. According to the CDC’s 2025 nonoccupational PEP recommendations, the standard course lasts 28 days.

PEP is an emergency measure rather than a routine prevention strategy. People who expect repeated or ongoing HIV exposure may benefit more from PrEP, or pre-exposure prophylaxis, after a healthcare professional confirms the appropriate testing and prevention plan.

PEP does not prevent pregnancy or other sexually transmitted infections, so additional testing, contraception, condoms, vaccination, or other preventive care may be appropriate depending on the exposure.

Who Should Consider PEP?

PEP should be evaluated when a potentially infectious body fluid comes into contact with a mucous membrane, non-intact skin, or through a penetrating injury and the circumstances present a substantial risk of HIV transmission. The decision depends on the type of exposure, the body fluid involved, the HIV status and viral suppression of the source when known, and whether the exposed person was already using PrEP correctly.

Examples that may warrant urgent PEP evaluation include:

• Condomless vaginal or anal sex when the partner has HIV without documented sustained viral suppression or when the partner’s HIV status is unknown and the exposure is considered substantial risk.
• A condom breaking or slipping during a potentially substantial-risk sexual exposure.
• Sharing needles, syringes, or other injection equipment.
• Sexual assault involving a potential HIV exposure.
• A workplace needlestick, sharps injury, or certain blood/body-fluid exposures.

PEP is intended for people who do not have HIV. Baseline HIV testing is therefore part of the evaluation, but the first dose should not be delayed when PEP is indicated and laboratory results are still pending.

Which Exposures Usually Do Not Require PEP?

PEP is not recommended when an exposure presents no substantial risk for HIV transmission. For example, contact with non-blood-contaminated saliva, urine, sweat, tears, or nasal secretions generally does not warrant HIV PEP. Intact skin contact also does not normally create a route for HIV transmission.

If the source person is known to have HIV and has documented sustained viral suppression, current CDC nonoccupational guidance generally does not recommend nPEP for exposures that would otherwise be assessed for HIV transmission risk. If the source’s viral-load information is uncertain, unavailable, or potentially outdated, a clinician should assess the situation rather than assuming there is no risk.

When Should You Start PEP?

You should start PEP as soon as possible after a possible substantial-risk HIV exposure. CDC recommends starting as soon as possible, ideally within 24 hours and no later than 72 hours.

1. Seek care immediately: do not wait until the next day if care is available now.
2. Do not wait for symptoms: early HIV infection may cause no symptoms, and symptoms cannot determine whether PEP is needed.
3. Do not delay an indicated first dose for laboratory results: testing can continue after PEP has been started.
4. Complete 28 days: take the prescribed regimen exactly as directed unless your healthcare professional changes or stops it.

CDC recommends providing the first nPEP dose as soon as possible, ideally within 24 hours of exposure and no later than 72 hours, followed by a 28-day course.

What If More Than 72 Hours Have Passed?

For a nonoccupational exposure, CDC does not routinely recommend starting nPEP more than 72 hours after exposure because evidence is insufficient to support later initiation. However, you should still seek medical care. A healthcare professional can arrange HIV testing, discuss symptoms of acute HIV infection, evaluate other STIs or hepatitis when appropriate, and make a follow-up testing and PrEP plan.

For certain high-risk occupational exposures presenting after 72 hours, the 2025 U.S. Public Health Service occupational PEP guidance recommends consultation with a clinician experienced in HIV treatment rather than assuming no further evaluation is needed.

How Do You Get PEP?

Contact a healthcare provider, urgent care clinic, or emergency department immediately after a possible substantial-risk HIV exposure. The HIV.gov Services Locator can also help you find PEP providers in the United States. Pharmacists can prescribe PEP in some states under state-specific rules.

A clinician will review what happened, when the exposure occurred, the type of body fluid and contact involved, any available information about the source, your HIV prevention history, medications, allergies, pregnancy status when relevant, and health conditions that could affect medication selection.

What Tests Are Needed Before and After Starting PEP?

Testing helps determine whether PEP is appropriate, selects a safe regimen, and checks for infections or health issues related to the exposure. Current CDC guidance recommends baseline evaluation, but an indicated first PEP dose should not be delayed while waiting for laboratory-based results.

Depending on the situation, baseline evaluation can include:

• HIV testing: typically a blood-based rapid or laboratory antigen/antibody test.
• Kidney function: serum creatinine helps guide selection and dosing of certain medicines.
• Liver tests: including ALT and AST.
• Hepatitis B testing: because several PEP medicines also act against hepatitis B and stopping them can require additional consideration in people with HBV.
• Pregnancy testing: when pregnancy is possible.
• STI testing: gonorrhea, chlamydia, syphilis, and other testing may be indicated after sexual exposure.
• Hepatitis C testing: when the exposure circumstances warrant it.

Special HIV testing considerations apply to people who recently used long-acting injectable antiretroviral prevention. Your healthcare professional can select the appropriate blood tests based on your history.

How Does PEP Work?

PEP uses a combination of antiretroviral medicines to interfere with HIV replication during the period after exposure when infection might otherwise become established. Starting early is important because HIV can establish infection quickly.

1. Start early: antiretroviral medicines are introduced before HIV has had more time to establish infection.
2. Maintain treatment: the medicines are taken for the full recommended 28-day course.
3. Follow up: HIV testing after the exposure is required because PEP is highly effective when taken correctly but is not guaranteed to prevent every infection.

The exact effectiveness of today’s PEP cannot be summarized accurately with one universal percentage for every type of exposure. Human evidence comes largely from observational data, while important timing and duration evidence also comes from animal studies. The CDC nevertheless considers modern three-drug PEP likely to reduce HIV acquisition when it is started promptly and taken as recommended.

What Medications Are in PEP?

The 2025 CDC nPEP recommendations use newer three-drug antiretroviral regimens. For most adults and adolescents without relevant contraindications, preferred options include:

• Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), available as a complete single-tablet regimen; or
• Dolutegravir (DTG) plus either tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF), together with either emtricitabine (FTC) or lamivudine (3TC).

The correct regimen can change based on age, weight, pregnancy, kidney or liver function, hepatitis B status, previous antiretroviral exposure, medication interactions, suspected drug resistance in the source, availability, and other clinical factors. Children require age- and weight-specific regimens.

Do not choose a PEP combination or change doses on your own. The goal is a regimen that is effective, tolerable, convenient, and safe enough for you to complete the full course.

PEP Side Effects and Drug Interactions

Modern PEP regimens are generally well tolerated. Depending on the medicines used, possible side effects can include nausea, diarrhea, headache, fatigue, abdominal discomfort, or sleep changes. Serious adverse effects are less common, but kidney, liver, or other medical problems can affect which regimen is safest.

Drug interactions also matter. Integrase inhibitors such as bictegravir and dolutegravir can interact with some medications and with mineral-containing products. Tell your prescriber about antacids, multivitamins, iron, calcium, magnesium, herbal products, and all other medicines you use. Follow the dosing and separation instructions given for your specific regimen.

If side effects make it difficult to keep taking PEP, contact your healthcare professional rather than stopping on your own. A different regimen or treatment for the side effect may be possible.

How Well Does PEP Work?

PEP is considered highly effective when taken as prescribed, but it is not 100% effective. Unlike PrEP, modern PEP does not have one reliable percentage that applies equally to every sexual, injection, or occupational exposure.

Your best chance of success comes from three factors:

1. Start as soon as possible: preferably within 24 hours and no later than 72 hours.
2. Complete the full 28 days: take the regimen exactly as prescribed.
3. Avoid additional exposures: use appropriate prevention measures during treatment and follow-up.

The frequently repeated figure that PEP is “more than 80% effective” comes largely from an older study of zidovudine after occupational exposure and should not be treated as a precise effectiveness rate for today’s three-drug nPEP regimens.

Can You Take PEP During Pregnancy or Breastfeeding?

Pregnancy and breastfeeding are not contraindications to nPEP. Current CDC guidance says pregnant or breastfeeding people should have rapid access to PEP when it is indicated. A clinician may involve an HIV or perinatal specialist because medication selection and counseling must consider both the patient and the fetus or infant.

If a breastfeeding person has a possible HIV exposure, counseling should also cover the small but important possibility of transmitting HIV through breast milk if acute HIV infection develops. Continuing, temporarily interrupting, or otherwise managing breastfeeding should be decided through individualized clinical counseling rather than by stopping PEP.

Infants themselves follow separate NIH perinatal and pediatric HIV recommendations for antiretroviral prophylaxis, presumptive therapy, and HIV NAT testing.

What Happens After PEP?

PEP care does not end with the final pill. Follow-up helps detect HIV if infection occurred, manage any other conditions related to the exposure, and decide whether ongoing HIV prevention is needed.

The healthcare professional or care team should generally check in soon after PEP is prescribed, with CDC recommending a follow-up within about 24 hours to confirm that the medicines were obtained and to review early tolerability and adherence.

HIV Testing After PEP

Current CDC nPEP guidance recommends follow-up HIV testing at approximately 4–6 weeks after exposure and final testing at approximately 12 weeks after exposure. Follow-up testing should generally use a laboratory HIV antigen/antibody test plus a diagnostic HIV NAT when available.

1. Baseline: establishes your HIV status before or at the time PEP starts, although it cannot rule out infection from an exposure that happened only hours or days earlier.
2. 4–6 weeks after exposure: provides an important interim check. Under specific circumstances, a clinician may decide this test can be deferred.
3. About 12 weeks after exposure: serves as the standard final HIV testing point in current CDC nPEP guidance.

Routine HIV testing at six months is not part of the standard 2025 nPEP follow-up schedule, although additional testing for HIV, hepatitis, or other infections can be recommended in special circumstances.

Next Prevention Steps

If you expect repeated or ongoing HIV exposure, discuss PrEP before finishing PEP. Current guidance allows an immediate transition from nPEP to PrEP for appropriate patients rather than deliberately creating an unprotected gap, with HIV testing incorporated into the transition and subsequent PrEP care.

The CDC’s current PrEP guidance includes daily oral and injectable options. The most suitable choice depends on how HIV exposure may occur, your medical history, kidney function when oral tenofovir-containing PrEP is considered, pregnancy considerations, and your preference.

Follow-Up Care And Monitoring

Keep the follow-up appointments recommended by your healthcare professional. These visits can be used to:

• Confirm that you obtained and are taking the PEP medicines.
• Manage side effects or medication-interaction problems.
• Complete HIV testing at the recommended times.
• Review STI, hepatitis, pregnancy, or other testing indicated by the original exposure.
• Discuss PrEP if future HIV exposures are possible.

Routine repeat kidney or liver tests are not necessary for everyone. Current CDC guidance recommends additional monitoring when baseline results are abnormal, symptoms develop, significant kidney or liver disease is present, pregnancy requires closer follow-up, or another clinical reason exists.

Frequently Asked Questions

What Are the Risks of Taking PEP?

Modern PEP is generally well tolerated. Depending on the regimen, side effects can include nausea, diarrhea, headache, fatigue, or abdominal discomfort. Kidney or liver problems and important drug interactions are possible with some medicines. Tell your clinician about all medications and supplements you use, and contact them if side effects make it difficult to continue treatment.

What Is the 2-1-1 Rule for PrEP?

2-1-1 is an event-driven PrEP schedule, not PEP. It uses emtricitabine/tenofovir disoproxil fumarate (F/TDF): two pills 2–24 hours before sex, one pill 24 hours after the first dose, and another pill 48 hours after the first dose. CDC says this off-label approach can be prescribed to selected adult gay and bisexual men, but it is not FDA-approved and is not recommended by CDC. It should not be generalized to other populations or used with active hepatitis B without appropriate medical guidance.

What Are the Key Elements of PEP Success?

Start PEP as soon as possible and no later than 72 hours after a substantial-risk exposure, complete the full 28-day regimen as prescribed, manage side effects promptly, avoid additional HIV exposures, and complete recommended follow-up HIV testing.

Is Taking PEP for 21 Days Effective?

Twenty-one days is not the recommended standard course. Current CDC guidance recommends 28 days, and there is not enough evidence to establish a 21-day course as an equally effective alternative. If you have stopped early, missed multiple doses, or cannot obtain the remaining medicine, contact your prescriber or pharmacist promptly for individualized advice rather than assuming the shorter course is sufficient.

What Should I Do If I Miss a PEP Dose?

Follow the instructions supplied with your specific medication and contact your pharmacist or prescriber if you are unsure, especially after multiple missed doses or a long interruption. Do not deliberately stop the remainder of the 28-day course because of one missed dose, and do not take extra medication unless the instructions for your prescribed regimen tell you to do so.

Can I Start PEP After 72 Hours?

CDC does not routinely recommend nonoccupational PEP when more than 72 hours have passed because evidence is insufficient to support later initiation. You should still seek medical care for HIV testing, follow-up planning, STI or hepatitis assessment when appropriate, and PrEP counseling. Certain high-risk occupational exposures presenting after 72 hours warrant expert consultation.

What Is the Difference Between PEP and PrEP?

PEP is emergency HIV prevention started after a possible exposure and taken for 28 days. PrEP is prevention used before future exposure and is designed for people who may have ongoing or repeated chances of encountering HIV. People finishing PEP can sometimes transition directly to PrEP after appropriate HIV testing and clinical assessment.

Conclusion

PEP provides an important way to reduce the chance of acquiring HIV after a substantial-risk exposure, but timing matters. Seek care immediately, ideally within 24 hours and no later than 72 hours. If PEP is prescribed, complete the full 28-day course, address side effects with your healthcare team, and keep the recommended follow-up HIV testing appointments. If future exposures are possible, ask whether transitioning to PrEP would provide better ongoing protection.

Sources

1. CDC — Antiretroviral Postexposure Prophylaxis Recommendations, United States, 2025 — timing, indications, preferred regimens, baseline testing, follow-up testing, pregnancy, breastfeeding, and transition to PrEP.
2. HIV.gov — Post-Exposure Prophylaxis (PEP) — patient-focused guidance on the 72-hour window, 28-day treatment, access, and effectiveness.
3. U.S. Public Health Service — 2025 Occupational HIV Exposure and PEP Guidelines — workplace exposures, occupational PEP timing, and follow-up.
4. CDC HIV Nexus — Clinical Guidance for PrEP — ongoing prevention, PrEP options, and 2-1-1 dosing guidance.
5. NIH ClinicalInfo — Antiretroviral Management of Infants With HIV Exposure — specialized management of in-utero, intrapartum, and breastfeeding exposure.
6. HIV.gov Services Locator — finding PEP providers and other HIV-related services in the United States.